IMMvention Therapeutix, Inc., a Durham early-stage biotechnology company focused on discovering and developing human ...

Patients taking Novo Nordisk’s Wegovy plus Veru’s enobosarm saw 71% lower lean mass loss than those who were taking Wegovy ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...

Novo Nordisk A/S, GE HealthCare Technologies Inc. Read MarketBeat.com (Jea Yu)'s latest article on Investing.com ...

Inc., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo Nordisk A/S to co ...

The microbial ecosystems within our mouths may affect our cognitive function as we age, according to a study. Interventions such as prebiotics, including dietary nitrate, have potential for delaying ...

Deals of the Year & Impact Awards entries spanned industries and investment levels. Here are the stories of this year’s picks ...

Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.

Veru's enobosarm showed significant body composition benefits in Phase 2b trials with semaglutide. Extension study results ...

As investors look ahead to data shortly from Veru Inc. with enobosarm, the weight-loss space remains hot, with Novo Nordisk A/S reporting favorable top-line results from a phase Ib/IIa trial ...

Socially responsible companies are businesses that integrate social and environmental considerations into their core operations and decision-making processes.

Versant Ventures continues to invest in the increasingly competitive obesity space, this time launching Helicore with $65 ...